Navigation Links
Savient Pharmaceuticals to Present Multiple Abstracts at The European League Against Rheumatism (EULAR) 2011 Annual Congress

EAST BRUNSWICK, N.J., April 28, 2011 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that three abstracts will be presented at the European League Against Rheumatism (EULAR) 2011 Annual Congress.  The conference will take place on May 25 - 28 in London, United Kingdom, and will feature the abstracts as two oral presentations and one poster presentation.

The first scheduled oral presentation and the poster session will address the prevalence of gout in Europe and current treatment practices and disease burdens for European gout patients using existing therapies. The second oral presentation will focus on long-term safety of KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy.  The presentation details are as follows:

  • Chronic Gout in Europe in 2010: Clinical Profile of 1,380 Patients in the U.K., Germany, France, Italy and Spain (Abstract # OP0112). This abstract will be presented in an oral presentation on Thursday, May 26, 2011 at 11:10 AM.
  • Safety and Efficacy of Long-Term Pegloticase (KRYSTEXXA®) Treatment in Adult Patients with Chronic Gout Refractory to Conventional Therapy (Abstract # OP0113). This data will be presented in an oral presentation on Thursday, May 26, 2011 at 11:20 AM.
  • Quality of Life, Work Impairment and Resource Utilisation Associated with Gout and Its Co-Morbidities Across Five EU Countries: Results from the European National Health and Wellness Survey (NHWS) (Abstract # FRI0275-HP). This data will be presented during the EULAR poster session on Friday, May 27, 2011 at 11:45 AM.

Additional details on these abstracts are available on the EULAR website at  


Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP").  Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA.  Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S. For more information, please visit the Company's website at


SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Pharmaceuticals to Present at the Bank of America Merrill Lynch 2011 Health Care Conference
2. Savient Pharmaceuticals to Hold First Quarter 2011 Financial Results
3. Savient Pharmaceuticals to Present at the ROTH 23rd Annual OC Growth Stock Conference
4. Savient Pharmaceuticals to Present at the 31st Annual Cowen & Co. Health Care Conference
5. Savient Pharmaceuticals Announces U.S. Launch of KRYSTEXXA™; Reports Fourth Quarter and Year-End 2010 Financial Results
6. Savient Pharmaceuticals to Hold Fourth Quarter and Year-End 2010 Results Conference Call on Friday, February 25, 2011
7. Savient Closes Sale of $230 Million in Convertible Senior Notes
8. Savient Announces Proposed Offering of $125 Million in Convertible Senior Notes
9. Savient Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
10. Savient Pharmaceuticals Names John H. Johnson Chief Executive Officer
11. Savient Pharmaceuticals Announces Search for CEO
Post Your Comments:
(Date:11/26/2015)... DUBLIN , Nov. 26, 2015 ... the addition of the "2016 Future Horizons ... Monitoring (TDM) Market: Supplier Shares, Country Segment Forecasts, ... offering. --> ... comprehensive analysis of the Japanese therapeutic drug monitoring ...
(Date:11/26/2015)... , November 26, 2015 ... addition of the "2016 Future Horizons ... of Abuse Testing Market: Supplier Shares, Country ... report to their offering. --> ... the "2016 Future Horizons and Growth ...
(Date:11/26/2015)... 26, 2015 ... of the  "2016 Future Horizons and ... Drug Monitoring (TDM) Market: Supplier Shares, ... Opportunities"  report to their offering.  ... the addition of the  "2016 Future ...
Breaking Medicine Technology:
(Date:11/28/2015)... (PRWEB) , ... November 28, 2015 , ... Trying to ... has created the COUCH BUDDY. "I conceived of this design due to personal experience ... for couch users. It promotes relaxation and convenience, as well as increases support. It ...
(Date:11/27/2015)... ... ... There is only one major question facing all law firms in the ... has not been an easy question to answer. Especially when the senior partners and ... don’t share the same discipline around working long hours. , In addition to ...
(Date:11/27/2015)... Denver, CO (PRWEB) , ... November 27, 2015 , ... ... U.S. cities are not changing the way that they are handling security in light ... increasing police and security presence in an attempt to stop an attack from reaching ...
(Date:11/27/2015)... ... November 27, 2015 , ... An inventor, from ... dispense prescription medications at home, so he invented the patent-pending ELECTRONIC M.D. , ... prescription medications. In doing so, it could help to prevent potential overdose situations. ...
(Date:11/27/2015)... ... 2015 , ... The print component of “Supporting Our Caregivers” ... New York, Minneapolis, South Florida, with a circulation of approximately 250,000 copies and ... vast social media strategy and across a network of top news sites and ...
Breaking Medicine News(10 mins):